Mydecine
From Wikipedia, the free encyclopedia
Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.[2][3][4]
 | |
| Industry | Pharmaceutical; Psychedelic medicine |
|---|---|
| Founded | 2020 in Denver, Colorado |
| Headquarters | , |
| Website | mydecine.com |
In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations.[4][5] However, the company was able to obtain more funding and did not shutdown.[4] Mydecine made the first legal import of magic mushrooms into Canada in 2021.[6][7]
Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003),[8][9][10] MYCO-004 (a patch-delivered tryptamine),[11][12] and MYCO-005 (a novel aza psilocin analogue with putatively better safety)[13][14][2] and the novel MDMA-like entactogens MYCO-002 (putatively safer),[15][16] MYCO-006 (short-acting),[17][18][5][3] and MYCO-007 (short-acting).[19][20][21][1]
Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) as short-acting MDMA analogues.[22][23][24]
